Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study. Issue 4 (3rd June 2022)

• Record Type: Journal Article
• Authors: Trujillo‐Santos, Javier; Farge‐Bancel, Dominique; Pedrajas, José María; Gómez‐Cuervo, Covadonga; Ballaz, Aitor; Braester, Andrei; Mahé, Isabelle; Villalobos, Aurora; Porras, José Antonio; Monreal, Manuel
• Other Names: Adarraga MD investigator.; Aibar J investigator.; Aibar MA investigator.; Amado C investigator.; Arcelus JI investigator.; Asuero A investigator.; Barba R investigator.; Barbagelata C investigator.; Barrón M investigator.; Barrón‐Andrés B investigator.; Blanco‐Molina A investigator.; Botella E investigator.; Camon AM investigator.; Casado I investigator.; Castro J investigator.; Castro M investigator.; Chasco L investigator.; Criado J investigator.; de Ancos C investigator.; del Toro J investigator.; Demelo‐Rodríguez P investigator.; Díaz‐Brasero AM investigator.; Díaz‐Peromingo JA investigator.; Di Campli MV investigator.; Dubois‐Silva A investigator.; Escribano JC investigator.; Espósito F investigator.; Falgá C investigator.; Farfán‐Sedano AI investigator.; Fernández‐Capitán C investigator.; Fernández‐Reyes JL investigator.; Fidalgo MA investigator.; Flores K investigator.; Font C investigator.; Font L investigator.; Francisco I investigator.; Gabara C investigator.; Galeano‐Valle F investigator.; García MA investigator.; García‐Bragado F investigator.; García de Herreros M investigator.; García de la Garza R investigator.; García‐Díaz C investigator.; García‐Hernáez R investigator.; García‐Raso A investigator.; Gil‐Díaz A investigator.; Giménez‐Suau M investigator.; Grau E investigator.; Guirado L investigator.; Gutiérrez J investigator.; Hernández‐Blasco L investigator.; Hernando E investigator.; Jara‐Palomares L investigator.; Jaras MJ investigator.; Jiménez D investigator.; Jiménez R investigator.; Jiménez‐Alfaro C investigator.; Joya MD investigator.; Lainez‐Justo S investigator.; Latorre A investigator.; Lima J investigator.; Llamas P investigator.; Lobo JL investigator.; López‐Jiménez L investigator.; López‐Miguel P investigator.; López‐Núñez JJ investigator.; López‐Reyes R investigator.; López‐Sáez JB investigator.; Lorenzo A investigator.; Madridano O investigator.; Maestre A investigator.; Marchena PJ investigator.; Martín‐Martos F investigator.; Martínez‐Urbistondo D investigator.; Mella C investigator.; Mercado MI investigator.; Moisés J investigator.; Morales MV investigator.; Muñoz‐Blanco A investigator.; Muñoz‐Rivas N investigator.; Navas MS investigator.; Nieto JA investigator.; Nofuentes‐Pérez E investigator.; Núñez‐Fernández MJ investigator.; Obispo B investigator.; Olid M investigator.; Olivares MC investigator.; Orcastegui JL investigator.; Osorio J investigator.; Otalora S investigator.; Otero R investigator.; Paredes D investigator.; Parra P investigator.; Pellejero G investigator.; Portillo J investigator.; Rivera‐Civico F investigator.; Rodríguez‐Chiaradía DA investigator.; Rodríguez‐Matute C investigator.; Rogado J investigator.; Rosa V investigator.; Ruiz‐Artacho P investigator.; Ruiz‐Giménez N investigator.; Ruiz‐Ruiz J investigator.; Ruiz‐Sada P investigator.; Salgueiro G investigator.; Sánchez‐Martínez R investigator.; Sánchez‐Muñoz‐Torrero JF investigator.; Sancho T investigator.; Soler S investigator.; Suárez‐Rodríguez B investigator.; Suriñach JM investigator.; Tirado R investigator.; Torres MI investigator.; Tolosa C investigator.; Uresandi F investigator.; Valero B investigator.; Valle R investigator.; Varona JF investigator.; Vidal G investigator.; Villares P investigator.; Zamora C investigator.; Engelen M investigator.; Vanassche T investigator.; Verhamme P investigator.; Hirmerova J investigator.; Malý R investigator.; Ait Abdallah N investigator.; Bertoletti L investigator.; Bura‐Riviere A investigator.; Catella J investigator.; Couturaud F investigator.; Crichi B investigator.; Debourdeau P investigator.; Espitia O investigator.; Falvo N investigator.; Helfer H investigator.; Lacut K investigator.; Le Mao R investigator.; Moustafa F investigator.; Poenou G investigator.; Quere I investigator.; Schellong S investigator.; Brenner B investigator.; Tzoran I investigator.; Nikandish R investigator.; Bilora F investigator.; Brandolin B investigator.; Ciammaichella M investigator.; Di Micco P investigator.; Imbalzano E investigator.; Maida R investigator.; Pace F investigator.; Pesavento R investigator.; Prandoni P investigator.; Quintavalla R investigator.; Rocci A investigator.; Siniscalchi C investigator.; Tufano A investigator.; Visonà A investigator.; Zalunardo B investigator.; Birzulis J investigator.; Skride A investigator.; Zaicenko A investigator.; Fonseca S investigator.; Martins F investigator.; Meireles J investigator.; Bosevski M investigator.; Bounameaux H investigator.; Mazzolai L investigator.; Ochoa‐Chaar CI investigator.; Weinberg I investigator.; Bui HM investigator.;
• Is Part Of: Research and practice in thrombosis and haemostasis. Volume 6:Issue 4(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-06-03
• Subjects: cancer -- cohort -- dalteparin -- enoxaparin -- LMWH -- recurrences -- tinzaparin -- venous thromboembolism; Thrombosis -- Periodicals; Hemostasis -- Periodicals; 616.135005
• DOI: 10.1002/rth2.12736
• Languages: English
• ISSNs: 2475-0379

Abstract

Abstract: Background: Venous thromboembolism (VTE) is a frequent complication in patients with cancer and a leading cause of morbidity and death. Objectives: The objective of the RIETECAT study was to compare the long‐term effectiveness and safety of enoxaparin versus dalteparin or tinzaparin for the secondary prevention of VTE in adults with active cancer. Methods: We used the data from the multicenter, multinational RIETE registry to compare the rates of VTE recurrences, major bleeding, or death over 6 months in patients with active cancer and acute VTE using full doses of enoxaparin versus dalteparin or tinzaparin, and a multivariable Cox proportional hazard model was used to analyze the primary end point. Results: From January 2009 to June 2018, 4451 patients with active cancer received full doses of the study drugs: enoxaparin, 3526 patients; and dalteparin or tinzaparin, 925 (754 + 171) patients. There was limited difference in VTE recurrences (2.0% vs 2.5%) and mortality rate (19% vs 17%) between the enoxaparin and dalteparin or tinzaparin subgroups. However, there was a slight numerical increase in major bleeding (3.1% vs 1.9%). Propensity score matching confirmed that there were no differences in the risk for VTE recurrences (adjusted hazard ratio [aHR], 0.81; 95% confidence interval [CI], 0.48‐1.38), major bleeding (aHR, 1.40; 95% CI, 0.80‐2.46), or death (aHR, 1.07; 95% CI, 0.88‐1.30) between subgroups. Conclusions: In RIETECAT, in patients with cancer and VTE receiving full‐dose enoxaparin or dalteparin or tinzaparin, no statistically significant differences were observed regarding effectiveness and safety outcomes over a 6‐month period.